Gilead Sciences, Inc. $GILD Shares Sold by Commonwealth of Pennsylvania Public School Empls Retrmt SYS

Commonwealth of Pennsylvania Public School Empls Retrmt SYS decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 288,589 shares of the biopharmaceutical company’s stock after selling 9,374 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Gilead Sciences were worth $35,421,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Paulson Wealth Management Inc. lifted its position in shares of Gilead Sciences by 1.8% in the fourth quarter. Paulson Wealth Management Inc. now owns 3,887 shares of the biopharmaceutical company’s stock valued at $477,000 after acquiring an additional 67 shares in the last quarter. Alpha Cubed Investments LLC lifted its position in shares of Gilead Sciences by 1.1% in the fourth quarter. Alpha Cubed Investments LLC now owns 6,619 shares of the biopharmaceutical company’s stock valued at $812,000 after acquiring an additional 75 shares in the last quarter. Personal CFO Solutions LLC lifted its position in shares of Gilead Sciences by 1.7% in the fourth quarter. Personal CFO Solutions LLC now owns 4,572 shares of the biopharmaceutical company’s stock valued at $561,000 after acquiring an additional 76 shares in the last quarter. Moss Adams Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 1.7% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 4,446 shares of the biopharmaceutical company’s stock valued at $546,000 after acquiring an additional 76 shares in the last quarter. Finally, Valued Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 12.5% in the fourth quarter. Valued Wealth Advisors LLC now owns 711 shares of the biopharmaceutical company’s stock valued at $87,000 after acquiring an additional 79 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on GILD shares. Jefferies Financial Group started coverage on Gilead Sciences in a research report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 price objective on the stock. Royal Bank Of Canada reduced their price objective on Gilead Sciences from $123.00 to $122.00 and set a “sector perform” rating on the stock in a research report on Friday, May 8th. Rothschild & Co Redburn reduced their price objective on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Morgan Stanley reduced their price objective on Gilead Sciences from $175.00 to $168.00 in a research report on Friday, May 8th. Finally, Deutsche Bank Aktiengesellschaft upped their price objective on Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Twenty-five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $156.93.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $134.43 on Monday. The business’s 50-day moving average price is $135.30 and its 200 day moving average price is $134.20. Gilead Sciences, Inc. has a twelve month low of $104.46 and a twelve month high of $157.29. The company has a market capitalization of $166.90 billion, a PE ratio of 18.31 and a beta of 0.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same period in the prior year, the business posted $1.81 earnings per share. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post -0.79 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be given a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.4%. Gilead Sciences’s dividend payout ratio is 44.69%.

Insider Buying and Selling

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $132.27, for a total transaction of $396,810.00. Following the transaction, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 53,000 shares of company stock worth $7,075,670. 0.30% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.